Bristol-Myers Squibb (BMY)
$45.99
0.22 (0.48%)
BMY Stock Quote Delayed 15 Minutes
Previous Close
$45.77
Market Cap
75.17B
PE Ratio
80.68
EPS
0.57
Volume (Avg. Vol.)
4,062
Day's Range
45.65 - 46.56
52-Week Range
44.30 - 63.69
Dividend & Yield
1.60 (3.48%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
5 Top Stock Trades for Wednesday — AGN, ABBV, FDX, MSFT, BB
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
3 Big Stock Charts for Tuesday: MGM Resorts, Electronic Arts and Advance Auto Parts
The stock charts of EA, AAP and MGM have run through the technical trading wringer in front of today's action.
Nasdaq Today: Celgene, Ulta, Caesars’ Buyout
Celgene and Bristol-Myers Squibb stocks took a hit, video games rallied and Caesars Entertainment entered into a $17.3 billion merger. Here's the Nasdaq Today report.
5 Top Stock Trades for Tuesday: CELG, BMY, CZR
Bristol-Myers Squibb, Celgene, Caesars Entertainment, Match Group and New Relic are our top stock trades for Tuesday.
Bristol-Meyers Squibb News: Why BMY Stock Is Falling Today
Bristol-Meyers Squibb news for Monday has BMY stock taking a beating after announcing a delay to its merger deal with Celgene.
2 Dividend Stocks to Buy That Are Better Than 3M Stock
MMM stock has fallen 25% in the past six weeks since announcing weaker-than-expected Q1 earnings. 3M stock has been weak since then.
Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat
Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up Thursday on an earnings per share and revenue beat.
3 Big Stock Charts for Thursday: Discovery, Norfolk Southern and Bristol-Myers Squibb
The stock charts of BMY, DISCA and NSC stock merit the closest looks headed into the latter part of the week.
Why Is Bristol-Myers Near 52-Week Lows?
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock's acquisition of Celgene isn't the only reason.
BMY Stock Looks Really Appetizing as the Celgene Merger Approaches
Is Bristol-Myers Squibb stock a buy now? If you're patient enough to wait out the merger jitters, there's a lot to like.
Is AstraZeneca Stock Worth Buying Before Earnings?
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
3 Big Stock Charts for Monday: Bristol-Myers Squibb, Centurylink and Campbell Soup Company
The stock charts of CTL, CPB and BMY look ready to start the new trading week on the verge of tradeworthy moves. Here are levels to watch.
Is Celgene Stock Still Worth Holding Onto in the Long Run?
Celgene and Bristol-Myers got the green light from shareholders to move forward on the deal. More upside awaits for CELG stock.
5 Top Stock Trades for Monday: Lyft, RH, Celgene, Wells Fargo
Restoration Hardware, Bristol-Myers, Celgene, Lyft's IPO and Wells Fargo are our top stock trades to watch for Monday.
Friday’s Vital Data: Square, Southwest Airlines and Celgene
Options trading was buzzing in Southwest Airlines, Celgene, and Square on Thursday. Here are the metrics that matter moving forward.
5 Top Stock Trades for Friday: CELG, SQ, FIT, BOX
Bristol-Myers deal for Celgene is in doubt, while Box, Square, JD.com and Fitbit are moving on earnings. Here's are top stock trades for Friday.
Celgene Stock (CELG) Slides Lower on Opposition to Bristol-Meyers Deal
Celgene stock was on its way down Thursday following news that major investors are against a deal with Bristol-Meyers (BMY).
Friday’s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard
Options trading was buzzing in Bristol-Myers, Activision Blizzard and Intel hursday. Here are the metrics that matter moving forward.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
